Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Bentley

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
European Child & Adolescent Psychiatry|May 1, 2012
Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorderEli R Lebowitz, Maria G Motlagh, Liliya Katsovich, et al.
British Journal of Clinical Pharmacology|July 19, 2012
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitorGretchen Bain, Christopher D King, Kevin Schaab, et al.
American Heart Journal|April 8, 2003
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 studyGad Cotter, Christopher P Cannon, Carolyn H McCabe, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
European Child & Adolescent Psychiatry|May 1, 2012
Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorderEli R Lebowitz, Maria G Motlagh, Liliya Katsovich, et al.
British Journal of Clinical Pharmacology|July 19, 2012
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitorGretchen Bain, Christopher D King, Kevin Schaab, et al.
American Heart Journal|April 8, 2003
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 studyGad Cotter, Christopher P Cannon, Carolyn H McCabe, et al.
Pageof 2